Axxcess Wealth Management LLC Sells 355 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Axxcess Wealth Management LLC cut its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,916 shares of the company’s stock after selling 355 shares during the quarter. Axxcess Wealth Management LLC’s holdings in CRISPR Therapeutics were worth $390,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $39,000. Western Pacific Wealth Management LP boosted its holdings in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. Finally, Spire Wealth Management boosted its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CRSP. Truist Financial lifted their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Bank of America cut their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Price Performance

CRSP opened at $41.22 on Friday. The company’s 50 day moving average price is $43.09 and its two-hundred day moving average price is $45.37. The firm has a market capitalization of $3.54 billion, a price-to-earnings ratio of -9.43 and a beta of 1.76. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $74.59.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares in the company, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock valued at $1,608,243 over the last ninety days. 4.10% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.